Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti
The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.
You may also be interested in...
More than a dozen new molecular entities launched for the treatment of cancer in 2012, advancing care for seriously ill people, but many carry price tags of $100,000 per year or more for treatment, escalating debate over cost of care and how best to direct limited healthcare resources.
Though it has left behind the “industrialized” R&D approaches from the 1990s, Glaxo thinks its R&D revolution has produced strong growth that will get it back into major markets and maintain an output of three to five significant drug approvals per year. With that progress in sight, the firm is ready to transform its manufacturing and commercial model in the same way it recreated R&D.
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.